₹ 1558.7
Key Takeaways
Risk factor
Negligible price volatility
Profitability factor
Very strong margins and returns
About
Cipla Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India, the United States, South Africa, and internationally. The company offers active pharmaceutical ingredients; and formulations in various therapeutic areas, such as MI, angina, heart failure, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, HIV, respiratory, urology, oncology, cardio-metabolism, child health, infectious diseases and...
Company Valuation
Based on key historical and expected multiples, the stock is fairly valued relative to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV/EBITD.
Target Price
The average target price of CIPLA.NS is 1664 and suggests 7% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendati
